Member Info for Bobat1234

Peeps selling out now will be paying over 2p if RNs drop

This is the issue with the markets. Shares with good news goes down and shares with no news goes 40-50%. This has been pulled back. This should have been over 2.5p. Also more news to come

It's the same tweet I also wrote earlier. Hopefully good news tomorrow

Https://www.thisismoney.co.uk/money/markets/article-15180653/amp/SMALL-CAP-MOVERS-British-biotech-help-dogs-live-longer-lives.html

Kabwe Zinc Mine Development Pipeline

Kabwe's next phase focuses on compiling and analysing geological data to better understand the ore body, along with data collection, digitalisation, and interpretation.

http://x.com/Shukaminerals_/status/1978002418219487393?t=eWTLfGwyd56mBKkjSpSE7g&s=19

Big day tomorrow. Peeps either in or out. News on Wednesday

Will also hold. See what the future brings

News tomorrow or Wednesday. Buys coming in

Very Bullish

https://www.tradingview.com/chart/?symbol=LSE%3AGENF

Rocket boosters launched. Buys coming in now

Will move to II

Cannot buy any large amounts

Should gover 1p plus. Rto

Lots of buys printed before close on Friday.

Mms filling orders

10-Oct-25 16:27:25 1.98 750,000 Unknown* 14.85k O

10-Oct-25 16:28:44 1.9999 500,000 Unknown* 10,000 O

10-Oct-25 16:28:23 1.94 500,000 Unknown* 9,700 O

10-Oct-25 16:27:56 1.924 500,000 Unknown* 9,620 O

10-Oct-25 15:21:35 1.93 1,000,000 Unknown* 19.30k O

10-Oct-25 15:20:49 1.933 997,766 Unknown* 19.29k

Couple of buys on Friday. Big week coming up

Genflow

Genflow has been powering higher and has hit our immediate target line at just under 2.5p .

Key support: keep above September resistance near 2p .

Next target: the upper parallel of a broadening triangle from summer points to around 4p by the end of next mweek if the move continues.

(Alliance News) - Genflow Biosciences PLC on Friday reported strong data from a proof-of-concept clinical trial of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs.

The London-based biotechnology firm said the gene therapy has now been administered for the second time in its ongoing trial involved 28 beagles aged 10 years and older.

In March, recipients received three different modalities of the therapy, with no ill or adverse effects observed, Genflow said.

The repeat administration showed an "excellent safety and tolerability profile", the company said.

The dogs are currently in a follow-up period which is expected to conclude in January.

Genflow said the results show the robustness of its gene therapy platform and its potential applicability beyond human health.

The SIRT6 gene plays a key role in DNA repair, metabolic regulation and resistance to age-related decline.

Genflow added that it aims to introduce longevity-based treatments into the animal health market, to target improved healthspan, vitality and lifespan in both companion and livestock animals.

"We're very encouraged by the continued safety validation of our SIRT6 therapy and by the strong engagement we're seeing from established players in the animal health industry," said Chief Executive Officer Eric Leire.

"The animal health market represents an attractive near-term commercial opportunity for Genflow, complementing our core human longevity programs while showcasing the broader potential of our gene therapy platform."

Genflow said it will continue to advance its animal health initiative towards the next stage of clinical evaluation.

Excellent exposure on thisismoney.

Mates rates done. Mms moving this back up now. Shook out the weak. This should have been over 3p

We're very encouraged by the continued safety validation of our SIRT6 therapy and by the strong engagement we're seeing from established players in the animal health industry.